Phenotypic ratio of serum amyloid in pre- and type 2 diabetes

A technology for prediabetes, type 2 diabetes

Inactive Publication Date: 2012-05-30
INTRINSIC BIOPROBES
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although long used as a biomarker of adequacy of a patient's diabetes treatment, previous conflicting data have hampered the use of HbA1C in diabetes determination

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Phenotypic ratio of serum amyloid in pre- and type 2 diabetes
  • Phenotypic ratio of serum amyloid in pre- and type 2 diabetes
  • Phenotypic ratio of serum amyloid in pre- and type 2 diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0041] Analysis of the phenotypic ratio of serum amyloid A in human plasma

[0042] An exemplary embodiment of the present invention is to measure the SAA phenotype ratio and use it as a biomarker to distinguish clinically determined sample groups. This exemplary embodiment was analyzed using the mass spectrometry immunoassay (MSIA) technique.

[0043] In this example, a human citrate plasma sample obtained from a patient newly diagnosed with NGT, IGT, or DM was analyzed. 237 plasma samples were obtained from NGT individuals, 98 plasma samples were obtained from IGT patients, and 25 plasma samples were obtained from DM patients, all of which were analyzed in the same way.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention is directed to diagnosing, determining, and / or monitoring type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by detecting levels and modulations of Serum amyloid A protein (SAA), SAA variants and / or the phenotypic ratio of SAA. The present invention is also directed to methods for identifying and evaluating therapeutic treatments for type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by monitoring SAA, SAA variants, and / or the phenotypic ration of SAA.

Description

Technical field [0001] The present invention relates to a method for measuring, diagnosing and / or evaluating prediabetes, type 2 diabetes, insulin resistance and related disorders by detecting the level and adjustment of the phenotype ratio of serum amyloid A (SAA). The present invention also relates to methods for screening molecules that modulate such ratios, and their use in treating and / or improving symptoms related to prediabetes, type 2 diabetes, insulin resistance and related disorders. Background of the invention [0002] Type 2 diabetes (also known as type 2 diabetes, non-insulin dependent diabetes or adult-onset diabetes) is a metabolic disease characterized by hyperglycemia. This condition is caused by a lack of insulin produced by the body or by the body's cells producing insulin resistance (insulin resistance). Since insulin is an essential substance for absorbing glucose from the blood, the disorder of insulin homeostasis eventually leads to loss of blood sugar con...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/16
CPCG01N2800/042G01N33/6893G01N2333/4709
Inventor U·A·基尔南D·内代利科维
Owner INTRINSIC BIOPROBES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap